XXXX : Clinico-pathological study with evaluation of biologic markers.

@entity1 @entity2675 @entity0 @entity5344 @entity5 @entity3012 @entity4910 @entity513 @entity247 @entity3 @entity5282
UNASSIGNED: 777 Background: In contrast with female @entity0 , there is limited data on the expression of biologic markers and significance of clinicopathologic features in @entity2675 . METHODS: We reviewed pathology and clinical data for 33 evaluable @entity1 with MBC from 1981-1999. Immunohistochemical staining for ER, PR, AR, and @entity4910 was performed. RESULTS: Mean @entity1 age was 61 years (range 35-80). 70% were Caucasian, 18% Hispanic, 12% African-American. 27% had a family history of @entity5344 in first-degree relatives. @entity1 presented as follows: with @entity247 (33%), with a painless mass (33%), with nipple inversion/discharge (27%). Mean @entity5 size was 1.7 cm (range 0.1- 5.0 cm). The @entity5 was retroareolar/central in 67% @entity1 . 88% had @entity513 while 12% had intracystic papillary DCIS. @entity5 grade was as follows: high-grade (15), intermediate-grade (17), and low-grade (1). 40% had @entity3 , 15% presented with dermal involvement, and 12% had nipple involvement. Regarding evaluable biological markers: 86% were ER+, 75% PR+, 89% AR+, 67% @entity4910 +. @entity3012 was 85% (FU range 15-240 months), DFS was 64%. Overall survival and disease free survival for each biomarker is provided in the table below. CONCLUSIONS: The majority of @entity5 highly expressed ER, PR, AR, and @entity4910 , which may have important therapeutic implications for @entity1 with @entity2675 . @entity1 with @entity5 that did not express AR and @entity4910 performed poorly. Larger future studies will hopefully help to elucidate the prognostic implications of @entity5282 and cell cycle regulator expression in this population. [Figure: see text] No significant financial relationships to disclose.
